Difference between revisions of "MAP3K20-AS1"
(Created page with "==Annotated Information== ===Approved Symbol=== MAP3K20-AS1 ===Approved Name=== MAP3K20 antisense RNA 1 ===Previous Symbols=== MLK7-AS1 ===Synonyms=== _ ===Chromosome=== 2q31....") |
|||
| (9 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
| − | === | + | ===Name=== |
| − | MAP3K20-AS1 | + | Approved symbol: MAP3K20-AS1 |
| − | + | ||
| − | MAP3K20 antisense RNA 1 | + | Approved name: MAP3K20 antisense RNA 1 |
| − | + | ||
| − | MLK7-AS1 | + | HGNC ID: HGNC:27935 |
| − | = | + | |
| − | + | Previous names: MLK7 antisense RNA 1 (non-protein coding); MLK7 antisense RNA 1 | |
| + | |||
| + | Previous symbols: MLK7-AS1 | ||
| + | |||
| + | RefSeq ID: NR_033882 | ||
| + | |||
| + | LncBook ID: [https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289162 HSALNT0289162] | ||
| + | |||
===Chromosome=== | ===Chromosome=== | ||
2q31.1 | 2q31.1 | ||
| − | === | + | |
| − | + | ===Characteristics === | |
| − | === | + | [[File:MLK7-AS1 epigenetically regulates miR-375 expression.jpg|right|thumb|MLK7-AS1 epigenetically regulates miR-375 expression]] |
| − | + | Please input characteristics information here. | |
| − | === | + | |
| − | + | ===Expression=== | |
| − | === | + | lncRNA MLK7-AS1 was significantly increased in gastric cancer tissues compared with in adjacent tissues<ref name="ref1" />. |
| − | + | ||
| + | ===Regulation=== | ||
| + | Please input regulation information here. | ||
| + | |||
| + | ===Function=== | ||
| + | MLK7-AS1 interacted with Dnmt1 and recruited it to miR-375 promotor, hyper-methylating miR-375 promotor and repressing miR-375 expression to inhibit gastric cancer growth, indicating that MLK7-AS1 may be a useful prognostic marker and therapeutic target for gastric cancer patients.<ref name="ref1" />. | ||
| + | |||
| + | ===Disease=== | ||
| + | Gastric cancer <ref name="ref1" /> | ||
| + | |||
| + | ===Evolution=== | ||
| + | Please input evolution information here. | ||
| + | |||
| + | ==Labs working on this lncRNA== | ||
| + | * Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China. | ||
| + | * Department of Ultrasound, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. | ||
| + | |||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> Quan Y, Zhang Y, Lin W, et al. Knockdown of long non-coding RNA MAP3K20 antisense RNA 1 inhibits gastric cancer growth through epigenetically regulating miR-375[J]. Biochem Biophys Res Commun, 2018, 497: 527-534. | ||
| + | </ref>(1) | ||
| + | </references> | ||
Latest revision as of 12:06, 11 August 2019
Contents
Annotated Information
Name
Approved symbol: MAP3K20-AS1
Approved name: MAP3K20 antisense RNA 1
HGNC ID: HGNC:27935
Previous names: MLK7 antisense RNA 1 (non-protein coding); MLK7 antisense RNA 1
Previous symbols: MLK7-AS1
RefSeq ID: NR_033882
LncBook ID: HSALNT0289162
Chromosome
2q31.1
Characteristics
Please input characteristics information here.
Expression
lncRNA MLK7-AS1 was significantly increased in gastric cancer tissues compared with in adjacent tissues[1].
Regulation
Please input regulation information here.
Function
MLK7-AS1 interacted with Dnmt1 and recruited it to miR-375 promotor, hyper-methylating miR-375 promotor and repressing miR-375 expression to inhibit gastric cancer growth, indicating that MLK7-AS1 may be a useful prognostic marker and therapeutic target for gastric cancer patients.[1].
Disease
Gastric cancer [1]
Evolution
Please input evolution information here.
Labs working on this lncRNA
- Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China.
- Department of Ultrasound, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
